# Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)

> **NCT04267497** · PHASE1 · COMPLETED · sponsor: **Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal** · enrollment: 13 (actual)

## Conditions studied

- Invasive Pulmonary Aspergillosis

## Interventions

- **DRUG:** Amphotericin B Liposomal 50 MG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04267497
- **Lead sponsor:** Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-18
- **Primary completion:** 2022-11-10
- **Final completion:** 2022-11-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267497, "Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04267497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*